P2D Bioscience has received a $320,000 federal grant to develop a novel class of anti-inflammatory drugs that target lung disease. Specifically, the to-be-developed drugs will be aimed at treating acute lung injury, acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD) and asthma. The first phase of work will assess the validity of the drugs’ […]
P2D Bioscience, which is developing a drug to treat attention-deficit/hyperactivity disorder, has received a $1.5 million grant from the National Institutes of Health. The Cincinnati-based company will use the grant to fund preclinical studies of its lead drug candidate, PD2007, and the money should take the company to the point of filing an Investigational New […]
A Cincinnati-based startup is looking to Indian investors to help fund studies of a drug that could treat attention deficit hyperactivity disorder (ADHD) without addictive side effects. P2D Bioscience is developing nine drug candidates, but its lead candidates are intended to treat ADHD, a condition that mainly affects children and is characterized by inattention, hyperactivity […]
